

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 05213-0229	SERIAL NO. <del>NOT YET</del> <del>AVAILABLE</del> 10/042347	FILING DATE Filed Herewith
APPLICANT O'REILLY, ET AL		GROUP

997 U.S. PTO  
10/042347  
01/11/98

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
STN	AK WO 95/29242	11/02/95	PCT		
	AL WO 95/25543	09/28/95	PCT		
	AM WO 93/16716	09/02/93	PCT		
	AN WO 91/10424	07/25/91	PCT		
	AO J58036391	03/03/83	Japan (Abstract)		

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	
AR	
AS	
AT	

EXAMINER <i>Ally</i>	DATE CONSIDERED 9/20/04
-------------------------	----------------------------

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO.	FILING DATE
05213-0229		NOT YET AVAILABLE	Filed Herewith
APPLICANT		GROUP	
O'REILLY, ET AL		10/04/2347	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
BA		Abe, N. et al., "Identification of a Novel Collagen Chain Represented by Extensive Interruptions in the Triple-Helical Region", <i>Biochem. and Biophys. Resch. Comm.</i> , Vol. 196, No. 2, pp. 576-582 (1993)	
BB		Algire, G.H. et al., "Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants", <i>J. Natl. Canc. Inst.</i> , Vol. 6, pp. 73-85 (1945)	
BC		Angiolillo, A.I. et al., "Human interferon-inducible Protein 10 is a potent inhibitor of angiogenesis in vivo", <i>J. Exp. Med.</i> , Vol. 182, pp. 155-162 (1995)	
BD		Brcm, H. et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas", <i>J. Neurosurg.</i> , Vol. 74, pp. 441-446 (1991)	
BE		Brockway, W. J. et al., "Measurement of the Binding of Antifibrinolytic Amino Acids to Various Plasminogens", <i>Arch. Biochem. Biophys.</i> , Vol. 151, pp. 194-199 (1972)	
BF		Browne, M.J. et al., "Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells", <i>Fibrinolysis</i> , Vol. 5, pp. 257-260 (1991)	
BG		Cao, Y. et al., "gro-β, α-C-X-C- Chemokine, Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice", <i>J. Exp. Med.</i> , Vol. 182, pp. 2069-2077 (1995)	
BH		Chen, C. et al., "A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors", <i>Canc Resch.</i> , Vol. 55, pp. 4230-4233 (1995)	
BI		Clapp, C. et al., "The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis", <i>Endocrinology</i> , Vol. 133, pp. 1292-1299 (1993)	
BJ		Cleary, S. Mulkerrin et al., "Purification and Characterization of Tissue Plasminogen Activator Kringle-2 Domain Expressed in <i>Escherichia coli</i> ", <i>Biochem.</i> , Vol. 28, pp. 1884-1891 (1989)	
BK		Dameron, K.M. et al., "Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1", <i>Science</i> , Vol. 265, pp. 1582-1584 (1994)	
BL		Folkman, J., "Tumor angiogenesis and tissue factor", <i>Nature Med.</i> Vol. 2, pp. 167-168 (1996)	
BM		Folkman, J., "What is the Evidence that Tumors are Angiogenesis Dependent?", <i>J. Natl Canc Inst.</i> , Vol. 82, pp. 4-6 (1990)	
BN		Folkman, J., "Angiogenesis in cancer, vascular, rheumatoid and other disease", <i>Nature Medicine</i> , Vol. 1, No. 1, pp. 27-31 (1995)	
BO		Folkman, J., "Long-term culture of capillary endothelial cells", <i>Proc. Natl. Acad. Sci. USA</i> 76, pp. 5217-5221 (1979)	
BP		Folkman, J. et al., "Induction of angiogenesis during the transition from hyperplasia to neoplasia", <i>Nature</i> , Vol. 339, pp. 58-61 (1989)	
BQ		Folkman, J. et al., "Tumor Behavior in Isolated Perfused Organs In Vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment", <i>Annals of Surgery</i> , Vol. 164, No. 3, pp. 491-501 (1996)	
BR		Folkman, J., "Angiogenesis and Its Inhibitors", <i>Important Advances in Oncology</i> , J.B. Lippincott Company, pp. 42-62 (1985)	
BS		Folkman, J., "Tumor Angiogenesis Therapeutic Implications", <i>NE J. of Med.</i> , No. 18, pp. 1182-1186 (1971)	
EXAMINER		DATE CONSIDERED	
EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		7/20/04	

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO. <del>NOT YET</del> AVAILABLE	FILING DATE
05213-0229		10/042347	Filed Herewith
APPLICANT		GROUP	
O'REILLY, ET AL			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
554	CA	Gavrieli, Y. et al., "Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation", <i>J. Cell Biol.</i> , Vol. 119, pp. 493-501 (1992)	
1	CB	Gimbrone, M.A. et al., "Tumor Growth and Neovascularization An Experimental Model using the Rabbit Cornea", <i>J. Natl. Canc. Inst.</i> , Vol. 52, No. 2 pp. 413-427 (1974)	
	CC	Gimbrone, M.A. et al., "Tumor Dormancy in Vivo by Prevention of Neovascularization", <i>J. of Experi. Med.</i> , Vol. 136, pp. 261-276 (1972)	
	CD	Good, D.J. et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin", <i>Proc. Nat. Acad. Sci. USA</i> , Vol. 87, pp. 6624-6628 (1990)	
	CE	Grant, D.S. et al., "Scatter factor induces blood vessel formation in vivo", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 99, pp. 1937-1941 (1993)	
	CF	Grant, D.S. et al., "Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro", <i>Cell</i> , Vol. 58, pp. 933-943 (1989)	
	CG	Gross, J.L. et al., "Modulation of Solid Tumor Growth in vivo by bFGF", <i>Proc. Amer. Assoc. Canc. Resh.</i> , Vol. 31, p. 79 (1990)	
	CH	Gross, J.L. et al., "Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro.", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 80, pp. 2623-2627 (1983)	
	CI	Gunzler, W.A. et al., "The Primary Structure of High Molecular Mass Urokinase from Human Urine", <i>Hoppe-Seyler's Z. Physiol. Chem.</i> , Vol. 363, pp. 1155-1165 (1982)	
	CJ	Gupta, S.K. et al., "A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 7779-7803 (1995)	
	CK	Holmgren, L. et al., "Dormancy of micrometastases Balanced proliferation and apoptosis in the presence of angiogenesis suppression", <i>Nature Medicine</i> , Vol. 1, No. 2, pp. 149-153 (1995)	
	CL	Homandberg, G.A. et al., "Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth", <i>Am. J. Path.</i> , Vol. 120, pp. 327-332 (1985)	
	CM	Hori, A. et al., "Suppression of Solid tumor Growth by Immunoneutralizing Monoclonal Antibody against Human Basic Fibroblast Growth Factor", <i>Canc. Resch.</i> , Vol. 51, pp. 6180-6184 (1991)	
	CN	Ingber, D. et al., "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth", <i>Nature</i> , Vol. 348, pp. 555-557 (1990)	
	CO	Johansson, J. et al., "Surfactant Protein B: Disulfide Bridges, Structural Properties, and Kringle Similarities", <i>Biochem.</i> , Vol. 30, pp. 6917-6921 (1991)	
	CP	Kandel, J. et al., "Neovascularization is Associated with a Switch to the Export of bFGF in the Multistep Development of Fibrosarcoma", <i>Cell</i> , Vol. 66, pp. 1095-1104 (1991)	
	CQ	Kim, K. J. et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo", <i>Nature</i> , Vol. 362, pp. 841-844 (1993)	
1	CR	Kivirikko, S. et al., "Primary Structure of the $\alpha 1$ Chain of Human Type XV Collagen and Exon-Intron Organization in the 3' Region of the Corresponding Gene", <i>J. Bio. Chem.</i> , Vol. 269, No. 7, pp. 4773-4779 (1994)	
EXAMINER		DATE CONSIDERED	
EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		9/20/04	

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO. <del>NOT YET</del> AVAILABLE	FILING DATE
05213-0229		Filed Herewith
APPLICANT	GROUP	
O'REILLY, ET AL	10/04/2347	

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

SM	DA	Knighton, D. et al., "Avascular and Vascular Phases of Tumor Growth in the Chick Embryo", <i>Br. J. Cancer</i> , Vol. 35, pp. 347-356 (1977)
	DB	Lein, W. M. et al., "The blood supply of experimental liver metastases. II. A Microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber", <i>Surgery</i> , Vol. 68, No. 2, pp. 334-340 (1970)
	DC	Lerch et al., "Localization of Individual Lysine-Binding Regions in Human Plasminogen and Investigations on Their Complex-Forming Properties", <i>European Journal of Biochemistry</i> , Vol. 107, No. 1, pp. 7-13 (1980)
	DD	Lokker, N.A. et al., "Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-met receptor", <i>Prot. Engin.</i> , Vol. 7, pp. 895-903 (1994)
	DE	Maione, T.E. et al., "Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides", <i>Science</i> , Vol. 247, pp. 77-79 (1990)
	DF	Marti, D. et al., "Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for $\omega$ -aminocarboxylic acids", <i>Eur. J. Biochem.</i> , Vol. 219, pp. 455-462 (1994)
	DG	McLean, J.W. et al., "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen", <i>Nature</i> , Vol. 330, pp. 132-137 (1987)
	DH	Menhart, N. et al., "Construction, Expression, and Purification of Recombinant Kringle 1 of Human Plasminogen and Analysis of Its Interaction with $\omega$ -Amino Acids", <i>Biochem.</i> , Vol. 30, pp. 1948-1957 (1991)
	DI	Millauer, B. et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant", <i>Nature</i> , Vol. 367, pp. 576-579 (1994)
	DJ	Moses, M.A. et al., "Identification of an Inhibitor of Neovascularization from Cartilage", <i>Science</i> , Vol. 248 (1990)
	DK	Muragaki, Y. et al., "Mouse col 18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 8763-8767 (1995)
	DL	Muthukkaruppan, V.R., "Angiogenesis in the Mouse Cornea", <i>Science</i> , Vol. 205, pp. 1416-1418 (1979)
	DM	Nelson, J. A. et al., "Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and angiogenesis", <i>Canc. Resch.</i> , Vol. 55, pp. 3772-3776 (1995)
	DN	Nguyen, M. et al., "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane", <i>Microvascular Research</i> , Vol. 47, pp. 31-49 (1994)
	DO	Nguyen, M. et al., "Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients", <i>J. of Nat. Canc. Inst.</i> , Vol. 85, No. 3, pp. 241-242 (1993)
	DP	O'Reilly et al., "Endogenous Inhibitors of Angiogenesis", <i>Proc. Am. Assoc. Canc. Resch.</i> , Vol. 37, p. 669 (1996)
	DQ	O'Reilly et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice", <i>Nature Medicine</i> , Vol. 2, No. 6, pp. 689-692 (1996)
	DR	O'Reilly et al., "The suppression of Tumor Metastases by a Primary Tumor", <i>Surgical Forum</i> , Vol. XLIV, pp. 474-476 (1993)
	DS	O'Reilly et al., "Angiostatin A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", <i>Cell</i> , Vol. 79, pp. 315-328 (1994)
	DT	O'Reilly et al., "Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth", <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , Vol. LIX, pp. 471-482 (1994)
	DU	Obeso, J. et al., "Methods in Laboratory Investigation/A Hemangioendothelioma-Derived Cell Line Its Use as a Model for the Study of Endothelial Cell Biology", <i>Laboratory Investigation</i> , Vol. 63, No. 2, p. 159 (1990)
	DV	Oh, S.K. et al., "Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 4229-4233 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO.	FILING DATE
05213-0229		NOT YET AVAILABLE	Filed Herewith
APPLICANT		GROUP	
O'REILLY, ET AL		10/042347	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
554	EA	Oh, S.P., "Cloning of cDNA and Genomic DNA Encoding Human Type VIII Collagen and Localization of the $\alpha 1$ (XVIII) Collagen Gene to Mouse Chromosome 10 and Human Chromosome 21", <i>Genomics</i> , Vol. 19, pp. 494-499 (1994)	
	EB	Parangi, S. et al., "Antiangiogenic therapy of transgenic mice impairs de novo tumor growth", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 2002-2007 (1996)	
	EC	Passaniti, A. et al., "Methods in Laboratory Investigation/A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor", <i>Lab. Invest.</i> , Vol. 67, No. 4, pp. 519-528 (1992)	
	ED	Ponting et al., "Plasminogen: a structural review", <i>Blood Coagulation and Fibrinolysis</i> , Vol. 3, pp. 605-614 (1992)	
	EE	Powell, J. R. et al., "Amino Acid Sequence Analysis of the Asparagine-288 Region of the Carbohydrate Variants of Human Plasminogen", <i>Biochem.</i> , Vol. 22, pp. 923-927 (1983)	
	EF	Rastinejad, F. et al., "Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene", <i>Cell</i> , Vol. 56, pp. 345-355 (1989)	
	EG	Rehn, M. et al., " $\alpha 1$ (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 4234-4238 (1994)	
	EH	Rehn, M. et al., "Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts", <i>J. Biol. Chem.</i> , Vol. 270, pp. 5705-4711 (1995)	
	EI	Robbins, K.C., "The Plasminogen-Plasmin Enzyme System", <i>Fibrinolysis</i> , pp. 340-357 (1987)	
	EJ	Sage, E.H. et al., "Inhibition of Endothelial Cell Proliferation by SPARC is Mediated through a $Ca^{2+}$ -Binding EF-Hand Sequence", <i>J. Cell. Biochem.</i> , Vol. 57, pp. 127-140 (1995)	
	EK	Sakamoto, N. et al., "Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH <sub>2</sub> ", <i>Canc. Resch.</i> , Vol. 51, pp. 903-906 (1991)	
	EL	Sambrook, J. et al., "Expression of Cloned Genes in Escherichia coli", <i>Molecular Cloning Second Edition</i> , Cold Spring Harbor Laboratories Press, pp. 17.37-17.41	
	EM	Schaller, J. et al., "Structural Aspects of the Plasminogen of Various Species", <i>Enzyme</i> , 40 pp. 63-69 (1988)	
	EN	Shi, G. et al., "Kringle Domains and Plasmin Denaturation", <i>Biochem. Biophys. Resch. Comm.</i> , Vol. 178, No. 1, pp. 360-368 (1991)	
	EO	Sottrup-Jensen, L. et al., "The Primary Structure of Human Plasminogen Isolation of Two Lysine-Binding Fragments and One "Mini-" Plasminogen (MW, 38,000) by Elastase-Catalyzed-Specific Limited Proteolysis", <i>Prog. in Chem. Fibrinolysis and Thrombolysis</i> , Vol. 3, pp. 191-209 (1978)	
	EP	Srivastava, A. et al., "The Prognostic Significance of Tumorascularity in Intermediate-Thickness (0.76-4.0mm Thick) Skin Melanoma", <i>Am. J. of Path.</i> , Vol. 133, No. 2, pp. 419-424 (1988)	
	EQ	Strieter, R.M. et al., "Interferon-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis", <i>Biochem. Biophys. Resch. Comm.</i> , Vol. 210, pp. 51-57 (1995)	
	ER	Studier, W.F. et al., "Use of T7 RNA polymerase to direct expression of cloned genes", <i>Methods Enzymol.</i> , Vol. 85, pp. 60-89 (1990)	
	ES	Teicher, B.A. et al., "Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents", <i>Int. J. Canc.</i> , Vol. 57, pp. 1-6 (1994)	
	ET	Tolsma, S.S. et al., "Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity", <i>J. Cell Biol.</i> , Vol. 122, pp. 497-511 (1993)	
	EU	Van Meir, E. et al., "Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells", <i>Nature Genetics</i> , Vol. 8, pp. 171-176 (1994)	
	EV	Voest, E. E. et al., "Inhibition of Angiogenesis in Vivo by Interleukin 12", <i>J. Natl. Can. Inst.</i> , Vol. 87, pp. 581-586 (1995)	
EXAMINER		DATE CONSIDERED	
EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		9/20/04	

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO.	FILING DATE
05213-0229		NOT YET AVAILABLE	Filed Herewith
APPLICANT		GROUP	
O'REILLY, ET AL		10/042347	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
SM ↓ V	FA	Walz, D.A. et al., "Amino acid sequence of human prothrombin fragments 1 and 2", <i>Proc. Natl. Acad. Sci.</i> , Vol. 74, pp. 1969-1973 (1977)	
	FB	Weidner, N. et al., "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma", <i>J. Natl. Canc. Inst.</i> , Vol. 84, pp. 1875-1887 (1992)	
	FC	Weidner, N. et al., "Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma", <i>Am. J. Path.</i> , Vol. 143, No. 2, pp. 401-409 (1993)	
	FD	Weidner, N. et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma", <i>NE J. of Med.</i> , Vol. 324, No. 1, pp. 1-8 (1991)	
	FE	Wiman, B. et al., "On the Specific Interaction Between the Lysine-Binding Sites in Plasmin and Complementary Sites In $\alpha_2$ -Antiplasmin and Fibrinogen", <i>Biochimica et Biophysica Acta</i> . Vol. 579, pp. 142-154 (1979)	
	FF	Yoshimura, T. et al., "Cloning, Sequencing, and Expression of Human Macrophage Stimulating Protein (MSP, MST1) Confirms MSP as a Member of the Family of Kringle Proteins and Locates the MSP Gene on Chromosome 3", <i>Laboratory of Immunobiology</i> , pp. 15461-15468 (1993)	
	FG		
	FH		
	FI		
	FJ		
FK			
FL			
FM			
FN			
FO			
FP			
EXAMINER		DATE CONSIDERED	
Stuff		9/20/04	

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	<del>09/115,689</del> 10/042347
Filing Date	May 20, 1999
First Named Inventor	M. Judah Folkman
Group Art Unit	1642
Examiner Name	S. Huff
Attorney Docket Number	05213-0229 (43170-219534)

997 U.S. PRO  
10/042347  
01/11/02

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	9/20/04
-----------------------	---	--------------------	---------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	<del>09/315,689</del> 10/042347
		Filing Date	May 20, 1999
		First Named Inventor	M. Judah Folkman
		Group Art Unit	1642
		Examiner Name	S. Huff
Sheet 2	of 2	Attorney Docket Number	05213-0229 (43170-219534)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
SH	3	Biezinger, Paul, et al.: "Systemic Inhibition of tumor growth and tumor metastases by intramuscular administration of the Endostatin gene" NATURE BIOTECHNOLOGY, vol. 17, April 1999, pp 343-348.	
	4	Dhanabal, Mohanraj, et al.: "Cloning, Expression, and <i>In Vitro</i> Activity of Human Endostatin" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, US ACADEMIC PRESS INC. ORLANDO, FL, vol. 258, no. 258, 1999, pp 345-352.	
	5	Ding, Yuan-Hua, et al.: "Zinc-dependent dimers observed in crystals of human endostatin" PROC. NATL. ACAD. SCI USA, vol. 95, no. 18, September 1998, pp. 10443-10448.	
	6	O'Reilly, Michael S., et al.: "Endostatin: and Endogenous Inhibitor of Angiogenesis and Tumor Growth" CELL, vol. 88, January 24, 1997, pp. 277-285.	
	7	Sasaki, Takako, et al.: "Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin" THE EMBO JOURNAL, vol. 17, no. 15, August 1998, pp. 4249-4256.	
	8	Ständker, Ludger, et al.: "Isolation and characterization of the circulating form of human endostatin" FEBS LETTERS, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 420, no. 420, 1997, pp. 129-133.	

Examiner Signature	<i>SHuff</i>	Date Considered	9/20/04
--------------------	--------------	-----------------	---------

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43170-249874)

Sheet 1 of 6

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number <sup>2</sup>	Kind Code <sup>3</sup> (if known)			
	1	60/80728		MIXSON, James A.	06/27/2000	

**RECEIVED**

AUG 15 2002

TECH CENTER 1600/2900

Examiner  
SignatureDate  
Considered

9/20/04

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	10/042,347
				Filing Date	01/11/2002
				First Named Inventor	O'Reilly et al.
				Group Art Unit	1642
				Examiner Name	Sheela Jitendra Huff
Sheet	2	of	6	Attorney Docket Number	05213-0880 (43170-249874)

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
SJA	2	Author:	Title: Chapter 12: Vectors for Gene Therapy		
		Publ:	Current Protocols in Human Genetics	Vol/Iss:	Pages: 1997
	3	Author:	Title: A versatile vector for gene and oligonucleotide transfer into cells in culture and <i>in vivo</i> : Polyethylenimine		
		Publ:	Proc. Natl. Acad. Sci. USA	Vol/Iss: 92	Pages: 7297-7301 Date: 08/1995
	4	Author:	Title: The potential of extrachromosomal replicating vectors for gene therapy		
		Publ:	TIG	Vol/Iss: 12 (11)	Pages: 463-466 Date: 11/1996
	5	Author:	Title: Genetic Mechanisms of Tumor Suppression by the Human p53 Gene		
		Publ:	Science	Vol/Iss: 250	Pages: 1576-1579 Date: 12/1990
	6	Author:	Title: Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin		
		Publ:	Human Gene Therapy	Vol/Iss: 7	Pages: 275-282 Date: 02/10/199
	7	Author:	Title: The structure of endothelial cell thrombospondin - Characterization of the heparin-binding domains		
		Publ:	Eur J Biochem	Vol/Iss: 168 (2)	Pages: 347-355 Date: 10/15/198
✓	8	Author:	Title: Regulation of Gene Expression <i>in Vivo</i> by Liposome-mediated Delivery of a Purified Transcription Factor		
		Publ:	The Journal of Biological Chemistry	Vol/Iss: 265 (18)	Pages: 10189-10192 Date: 06/25/199

Examiner Signature	<i>Sheela Huff</i>	Date Considered	9/20/04
--------------------	--------------------	-----------------	---------

\*Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/APP

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (4379-10874)

Sheet 3 of 6

**RECEIVED****OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

AUG 15 2002

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number, publisher, city and/or country where published
558	9	<p><b>Author:</b> DIXIT, V.M. et al.      <b>Title:</b> A monoclonal antibody against human thrombospondin inhibits platelet aggregation</p> <p><b>Publ:</b> Proc. Natl. Acad. Sci. USA      <b>Vol/Iss:</b> 82      <b>Pages:</b> 3472-3476      <b>Date:</b> 05/1985</p>
	10	<p><b>Author:</b> FAN et al.      <b>Title:</b> Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy</p> <p><b>Publ:</b> Trends in Pharmacological Sciences      <b>Vol/Iss:</b> 16 (2)      <b>Pages:</b> 57-66      <b>Date:</b> 02/95</p>
	11	<p><b>Author:</b> FIDLER et al.      <b>Title:</b> The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis</p> <p><b>Publ:</b> Cell      <b>Vol/Iss:</b> 79(2)      <b>Pages:</b> 185-188      <b>Date:</b> 10/21/94</p>
	12	<p><b>Author:</b> FUJIWARA, T. et al.      <b>Title:</b> Induction of Chemosensitivity in Human Lung Cancer Cells <i>in Vivo</i> by Adenovirus-mediated Transfer of the Wild-Type p53 Gene</p> <p><b>Publ:</b> Cancer Research      <b>Vol/Iss:</b> 54      <b>Pages:</b> 2287-2291      <b>Date:</b> 05/01/1999</p>
	13	<p><b>Author:</b> GOLDMAN, C.K. et al.      <b>Title:</b> In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer</p> <p><b>Publ:</b> Nature Biotechnology      <b>Vol/Iss:</b> 15      <b>Pages:</b> 462-466      <b>Date:</b> 05/1997</p>
	14	<p><b>Author:</b> HAWKINS, MICHAEL J. M.D.      <b>Title:</b> Clinical trials of antiangiogenic agents</p> <p><b>Publ:</b> Current Opinion in Oncology      <b>Vol/Iss:</b> 7      <b>Pages:</b> 90-93      <b>Date:</b> 1995</p>
	15	<p><b>Author:</b> KING, RALPH P. Jr.      <b>Title:</b> Novel Cancer Approach From Noted Scientist Hits Stumbling Block</p> <p><b>Publ:</b> Wall Street Journal      <b>Vol/Iss:</b>      <b>Pages:</b> A1, A8      <b>Date:</b> 11/12/1999</p>

Examiner  
SignatureDate  
Considered

9/20/04

\*Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitution for Form 1449/A/PT <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			Complete if Known		
			Application No.	10/042,347	
			Filing Date	01/11/2002	
			First Named Inventor	O'Reilly et al.	
			Group Art Unit	1642	
			Examiner Name	Sheela Jitendra Huff	
Sheet	4	of	6	Attorney Docket Number	05213-0880 (1170-249874)

AUG 15 2002

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
SDH	16	<b>Author:</b> KOSFELD, M.D. et al. <b>Title:</b> Identification of a New Cell Adhesion Motif in Two Homologous Peptides from the COOH-terminal Cell Binding Domain on Human Thrombospondin <b>Publ:</b> The Journal of Biological Chemistry <b>Vol/Iss:</b> 268 (12) <b>Pages:</b> 8808-8814 <b>Date:</b> 1993
	17	<b>Author:</b> LESOON-WOOD, L.A. et al. <b>Title:</b> Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Tumor in Nude Mice <b>Publ:</b> Human Gene Therapy <b>Vol/Iss:</b> 6 <b>Pages:</b> 395-405 <b>Date:</b> 04/1995
	18	<b>Author:</b> MAIONE, T.E. et al. <b>Title:</b> Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity <b>Publ:</b> Cancer Research <b>Vol/Iss:</b> 51 <b>Pages:</b> 2077-2083 <b>Date:</b> 04/15/199
	19	<b>Author:</b> MARSHALL, ELIOT <b>Title:</b> Gene Therapy's Growing Pains <b>Publ:</b> Science <b>Vol/Iss:</b> 269 <b>Pages:</b> 1050-1055 <b>Date:</b> 08/25/199
	20	<b>Author:</b> O'REILLY et al. <b>Title:</b> Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth <b>Publ:</b> Cell <b>Vol/Iss:</b> 88 <b>Pages:</b> 277-285 <b>Date:</b> 01/24/97
	21	<b>Author:</b> PARK et al. <b>Title:</b> Development of liposome- and anti-HER2 immunoliposome/plasmid complexes for efficient and selective gene therapy <b>Publ:</b> Proceedings of the American Association for Cancer Research <b>Vol/Iss:</b> 38 <b>Pages:</b> 342 <b>Date:</b> 03/1997
	22	<b>Author:</b> PASQUALINI, R. et al. <b>Title:</b> $\alpha_v$ Integrins as receptors for tumor targeting by circulating ligands <b>Publ:</b> Nature Biotechnology <b>Vol/Iss:</b> 15 <b>Pages:</b> 542-546 <b>Date:</b> 06/1997

Examiner Signature	<i>Shuff</i>	Date Considered	9/20/04
--------------------	--------------	-----------------	---------

'Unique citation designation number. 'See attached Kinds of U.S. Patent Documents. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/P <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known		
				Application No	10/042.347	
				Filing Date	01/11/2002	
				First Named Inventor	O'Reilly et al.	
				Group Art Unit	1642	
				Examiner Name	Sheela Jitendra Huff	
Sheet	5	of	6	Attorney Docket Number		05213-0880 (43170-249874)

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
STJ	23	Author: PASQUALINI, R. et al.	Title: Organ targeting <i>in vivo</i> using phage display peptide libraries		
		Publ:			
		Nature	Vol/Iss: 380	Pages: 364-166	Date: 03/28/199
	24	Author: SAIKI et al.	Title: Inhibition of Tumor Angiogenesis by a Synthetic Cell-adhesive Polypeptide Containing the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD)		
		Publ:			
		Jpn. J. Cancer Research	Vol/Iss: 81	Pages: 668-675	Date: 1990
	25	Author: SHEIKH et al.	Title: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines		
		Publ:			
		Oncogene	Vol/Iss: 11	Pages: 1899-1905	Date: 1995
	26	Author: TANAKA, T. et al.	Title: Viral vector-mediated transductions of a modified platelet factor 3 cDNA inhibits angiogenesis and tumor growth		
		Publ:			
		Nature Medicine	Vol/Iss: 3	Pages: 437-442	Date: 04/1997
	27	Author: WEINSTAT-SASLOW, D.L. et al.	Title: Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and Angiogenesis		
		Publ:			
		Cancer Research	Vol/Iss: 54	Pages: 6504-6511	Date: 1994
	28	Author: XU, M. et al.	Title: In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes		
		Publ:			
		Molecular Genetics and Metabolism	Vol/Iss: 64	Pages: 001-005	Date: 1998
	29	Author: XU, M. et al.	Title: Gene Therapy with P53 and a Fragment of Thrombospondin 1 Inhibits Human Breast Cancer <i>in Vivo</i>		
		Publ:			
		Molecular Genetics and Metabolism	Vol/Iss: 63	Pages: 103-109	Date: 1998

Examiner Signature	<i>Sheela Huff</i>	Date Considered	9/20/04
--------------------	--------------------	-----------------	---------

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitution for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	10/042,347
				Filing Date	01/11/2002
				First Named Inventor	O'Reilly et al.
				Group Art. Unit	1642
Examiner Name	Sheela Jitendra Huff				
Sheet	6	of	6	Attorney Docket Number	05213-0880 (43170-249874)
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
SJA	30	Author: XU, M. et al. Title: Parenteral Gene Therapy with p53 Inhibits Human Breat Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity Publ: Human Gene Therapy Vol/Iss: 8 Pages: 177-185 Date: 01/20/199			
	31	Author: ZABRENETZKY, V. et al. Title: EXPRESSION OF THE EXTRACELLULAR MATRIX MOLECULE THROMBOSPONDIN INVERSELY CORRELATES WITH MALIGNANT PROGRESSION IN MELANOMA, LUNG AND BREAST CARCINOMA CELL Publ: Int. J. Cancer Vol/Iss: 59 Pages: 191-195 Date: 1994			
	32	Author: ZHU, N. et al. Title: Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice Publ: Science Vol/Iss: 261 Pages: 209-211 Date: 07/09/199			

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

Examiner Signature	<i>Shuff</i>	Date Considered	9/20/04
--------------------	--------------	-----------------	---------

<sup>1</sup>Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.